Acadia Pharmaceuticals | ACAD - Current Assets



Acadia Pharmaceuticals reported $960.55M in Current Assets for its fiscal quarter ending in June of 2025.


Current Assets Change Date
Acadia Pharmaceuticals USD 960.55M 89.61M Jun/2025
ALKERMES USD 1.64B 156.24M Jun/2025
Alnylam Pharmaceuticals USD 3.64B 375.44M Jun/2025
Biogen USD 7.97B 341.7M Jun/2025
BioMarin Pharmaceutical USD 3.81B 337.43M Jun/2025
Bristol-Myers Squibb USD 33.22B 2.44B Jun/2025
Corcept Therapeutics USD 443.11M 4.61M Jun/2025
Cytokinetics USD 886.54M 69.51M Jun/2025
Eisai JPY 763.15B 35.49B Jun/2025
Eli Lilly USD 49.85B 8.59B Jun/2025
Incyte USD 3.64B 411.91M Jun/2025
J&J USD 71.55B 15.66B Mar/2025
Moderna USD 6.17B 595M Jun/2025
Neurocrine Biosciences USD 1.75B 111M Jun/2025
Pfizer USD 43.7B 2.16B Jun/2025
Prothena USD 385.48M 99.93M Jun/2025
PTC Therapeutics USD 2.27B 43.53M Jun/2025
Sarepta Therapeutics USD 2.66B 224.45M Jun/2025
Ultragenyx Pharmaceutical USD 719.79M 20.63M Jun/2025
Vertex Pharmaceuticals USD 10.43B 419.1M Jun/2025